Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Shares of oversold pharmaceutical giant Biogen (NASDAQ:BIIB) are up about $4.40 on the day. While we’re not seeing any ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

In early trading on Tuesday, shares of Biogen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.2%. Year to date, Biogen has lost about 5.0% of its value.

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell.

It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...